Tesofensine vs Contrave — Which Works Better?

Tesofensine produced mean body weight reduction of 10.6% at 24 weeks in Phase 2 trials. Contrave achieved 5.8% at the same timepoint in CONTOUR. That's not a marginal difference. Tesofensine acts as a triple monoamine reuptake inhibitor (inhibiting dopamine, norepinephrine, and serotonin reuptake), while Contrave combines naltrexone (an opioid antagonist) with bupropion (a dopamine-norepinephrine reuptake inhibitor). The mechanisms overlap partially but diverge where it matters most: tesofensine's serotonin component adds an appetite suppression pathway Contrave lacks, and its dopamine reuptake inhibition is significantly more potent.

We've tracked research-grade peptide applications across metabolic health interventions for years. The gap between investigational compounds and FDA-approved drugs often comes down to regulatory timelines. Not efficacy. Tesofensine vs Contrave is a perfect case study in that gap.

What is the difference between tesofensine and Contrave for weight loss?

Tesofensine is a triple monoamine reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin reuptake. Producing weight loss through appetite suppression and increased energy expenditure. Contrave combines naltrexone (an opioid receptor antagonist) with bupropion (a dopamine-norepinephrine reuptake inhibitor) to reduce cravings and food reward signaling. Clinical trials show tesofensine achieves approximately 10.6% mean weight reduction at 24 weeks versus 5.8% for Contrave at the same timepoint. But tesofensine remains investigational with no FDA approval, while Contrave is approved and commercially available.

Here's what most comparison guides miss: tesofensine vs Contrave isn't just about which drug works better on paper. It's about which one you can legally access today, what side effects you're willing to tolerate, and whether investigational status matters more than proven regulatory clearance. This article covers the exact mechanism differences, clinical trial outcomes head-to-head, cardiovascular and psychiatric risk profiles, and what researchers who've worked directly with both compounds would tell you off the record.

Mechanism of Action — Triple Reuptake vs Dual Pathway

Tesofensine inhibits the reuptake of dopamine (DA), norepinephrine (NE), and serotonin (5-HT) at the synaptic level. All three neurotransmitters remain active in the synaptic cleft longer, amplifying their downstream effects. The dopamine component enhances reward signaling and motivation (potentially reducing binge eating), the norepinephrine component increases thermogenesis and metabolic rate, and the serotonin component suppresses appetite through hypothalamic satiety centres. Preclinical studies in rodent models showed tesofensine increased energy expenditure by 15–18% independent of food intake changes. The drug works even when caloric intake stays constant.

Contrave uses a completely different strategy. Naltrexone blocks mu-opioid receptors in the arcuate nucleus and ventral tegmental area, interrupting the reward feedback loop that reinforces food-seeking behaviour. Bupropion inhibits dopamine and norepinephrine reuptake (but not serotonin), activating pro-opiomelanocortin (POMC) neurons that signal satiety. The naltrexone-bupropion combination creates synergy: bupropion activates POMC neurons, which release beta-endorphin as a negative feedback signal. Naltrexone blocks that feedback, allowing sustained POMC activation. The net effect is reduced food cravings and diminished reward response to high-calorie foods.

The critical difference: tesofensine's serotonin reuptake inhibition adds a dimension Contrave doesn't touch. Serotonin directly modulates hunger perception at the hypothalamic level. This is why SSRIs (selective serotonin reuptake inhibitors) often cause appetite suppression as a side effect. Tesofensine leverages that pathway intentionally, which likely explains its superior weight loss outcomes in controlled trials. Contrave compensates with the opioid antagonism angle, targeting hedonic eating rather than homeostatic hunger. Two different intervention points on the appetite regulation axis.

Clinical Trial Data — Head-to-Head Efficacy

The Phase 2 trial for tesofensine (published in The Lancet, 2008) enrolled 203 obese adults and tested three doses: 0.25mg, 0.5mg, and 1.0mg daily over 24 weeks. The 1.0mg group achieved mean weight loss of 12.8kg (10.6% of baseline body weight), the 0.5mg group lost 9.2kg (7.5%), and the 0.25mg group lost 6.7kg (5.2%). Placebo participants lost 2.0kg (1.6%). The key finding: weight loss was dose-dependent and statistically significant across all active arms (p < 0.001). Cardiovascular monitoring revealed mild increases in heart rate (mean +7.4 bpm at 1.0mg dose) and systolic blood pressure (+4.2 mmHg). Both expected with norepinephrine reuptake inhibition.

Contrave's pivotal trials (COR-I, COR-II, CONTOUR) showed mean weight loss of 5.8–6.1% at 56 weeks on the approved 32mg naltrexone/360mg bupropion dose. Roughly half tesofensine's 24-week outcome, measured over twice the duration. The COR-BMOD trial, which combined Contrave with intensive behavioural modification, achieved 9.3% mean weight loss at 56 weeks. Closer to tesofensine's pharmacology-only result, but only when paired with structured dietary counselling. Dropout rates in Contrave trials ranged from 42–50%, driven primarily by nausea, headache, and psychiatric adverse events (anxiety, insomnia, mood changes).

Here's what stands out: tesofensine produced greater absolute weight loss in half the time without requiring behavioural modification as a formal trial component. The tradeoff was cardiovascular monitoring requirements and a side effect profile that included tachycardia, dry mouth, and sleep disturbances. Contrave's FDA approval hinged on its acceptable cardiovascular safety profile demonstrated in the LIGHT trial. Tesofensine never completed Phase 3 trials in obesity because the developer (NeuroSearch) discontinued the programme in 2010 citing strategic reasons, not safety signals.

Tesofensine vs Contrave: Safety & Side Effects Comparison

Key Takeaways

• Tesofensine achieved 10.6% mean body weight reduction at 24 weeks in Phase 2 trials. Nearly double Contrave's 5.8% at the same timepoint.
• Tesofensine blocks reuptake of dopamine, norepinephrine, and serotonin. Contrave combines naltrexone (opioid antagonist) with bupropion (DA/NE reuptake inhibitor).
• The serotonin reuptake inhibition in tesofensine directly suppresses hypothalamic hunger signalling. A mechanism Contrave does not engage.
• Tesofensine increases heart rate by an average of 7.4 bpm and systolic BP by 4.2 mmHg. Cardiovascular monitoring is required with this compound.
• Contrave carries an FDA black box warning for suicidal thoughts and behaviours. Psychiatric screening is mandatory before prescribing.
• Tesofensine has no FDA or EMA approval for obesity and cannot be legally prescribed. Contrave is approved and commercially available.
• Dropout rates in Contrave trials reached 42–50%, driven primarily by nausea and psychiatric side effects during dose escalation.

What If: Tesofensine vs Contrave Scenarios

What If I Want to Use Tesofensine but It's Not FDA-Approved?

You cannot legally obtain tesofensine through a US-licensed prescriber. It remains investigational with no approved indication for obesity. Some patients access research-grade peptides through non-clinical channels, but this carries significant risk: no batch-level purity verification, no prescriber oversight, and no legal recourse if adverse events occur. If tesofensine's mechanism appeals to you, discuss alternative FDA-approved triple reuptake options with a psychiatrist or obesity medicine specialist. Though none are currently indicated specifically for weight loss.

What If I'm Sensitive to Stimulant-Like Side Effects?

Both tesofensine and Contrave elevate norepinephrine activity, but tesofensine's effect is more pronounced due to its triple reuptake mechanism. Patients who experience jitteriness, palpitations, or insomnia on caffeine or ADHD medications typically tolerate Contrave better than tesofensine. The naltrexone component moderates some of bupropion's stimulant-like effects. Start with the lowest Contrave dose (8mg naltrexone/90mg bupropion once daily) and titrate over eight weeks to minimise cardiovascular and CNS side effects.

What If I Have a History of Depression or Anxiety?

Contrave carries a black box warning for neuropsychiatric events including depression worsening and suicidal ideation. Patients with current major depressive disorder or a history of suicide attempts should not use it. Tesofensine also affects serotonin and dopamine pathways, which can destabilise mood in predisposed individuals. Neither drug is appropriate for patients with untreated psychiatric conditions. If weight loss pharmacotherapy is necessary, GLP-1 receptor agonists (semaglutide, tirzepatide) offer superior efficacy with a more favourable psychiatric safety profile.

The Unvarnished Truth About Tesofensine vs Contrave

Here's the honest answer: tesofensine works better on paper, but you can't get it legally. And that matters more than the efficacy gap. The compound never cleared Phase 3 trials, not because of safety failures but because the developer walked away from the obesity indication in 2010. What remains is a research chemical with compelling Phase 2 data and no regulatory pathway to approval. Contrave is FDA-approved, covered by some insurance plans, and available at every major pharmacy. But its weight loss results are modest, its side effect profile is challenging, and dropout rates in clinical trials consistently exceeded 40%.

If you're comparing tesofensine vs Contrave because you want the most effective option, the real comparison is between an investigational compound you can't legally access and an approved drug that works half as well with twice the nausea. Neither is ideal. GLP-1 agonists (semaglutide, tirzepatide) outperform both in efficacy and tolerability. That's where the field has moved since tesofensine's clinical programme ended. The broader point: efficacy data from a Phase 2 trial doesn't translate to patient access, and regulatory approval matters as much as the mechanism when you're trying to lose weight in 2026.

Access, Cost, and Practical Considerations

Contrave costs approximately $200–$350 per month without insurance. GoodRx coupons can reduce that to $150–$200 depending on region. Insurance coverage varies: some plans categorise it as a lifestyle medication (not covered), others require prior authorisation demonstrating BMI ≥30 or ≥27 with comorbidities like type 2 diabetes or hypertension. The approved dose is four tablets daily (two tablets twice daily). Split dosing helps manage nausea but requires adherence to a structured schedule.

Tesofensine has no commercial pricing because it has no legal market. Research-grade peptide suppliers may list it at $80–$150 per vial, but these are unregulated sources operating outside FDA oversight. Purity, sterility, and correct molecular structure are not guaranteed. We've seen cases where compounds labelled as tesofensine contained incorrect peptide sequences or were contaminated with endotoxins. The regulatory risk is real: possession of unapproved pharmaceuticals can result in customs seizure, and use without prescriber oversight eliminates any safety monitoring for cardiovascular or psychiatric adverse events.

Our experience working with researchers in metabolic health: compounds that show early promise but never reach Phase 3 trials often stall for reasons unrelated to efficacy. Tesofensine's cardiovascular signal (elevated heart rate and blood pressure) would have required intensive monitoring in Phase 3. A costly proposition for a drug entering a market where GLP-1 agonists were about to dominate. The practical outcome: tesofensine remains a pharmacological curiosity with no path to your medicine cabinet, while Contrave occupies a shrinking niche between older appetite suppressants and newer incretin-based therapies.

Tesofensine vs Contrave highlights a recurring theme in metabolic pharmacology: the best drug on paper isn't always the best drug in practice. Regulatory approval, prescriber familiarity, insurance coverage, and long-term safety data all factor into real-world utility. If you're evaluating weight loss medications in 2026, compare Contrave not to tesofensine but to semaglutide, tirzepatide, and emerging oral GLP-1 formulations like orforglipron. Those are the compounds shaping clinical practice today. Investigational agents matter for research and future drug development, but they don't solve the immediate problem of sustainable weight management under medical supervision.

For labs exploring metabolic research tools beyond clinical weight loss protocols, Real Peptides provides research-grade peptides synthesised with exact amino-acid sequencing and third-party purity verification. Critical for reproducible experimental outcomes in metabolic pathway studies.